Is Warfarin a Contraindication to TNK?
Warfarin therapy is NOT an absolute contraindication to tenecteplase (TNK), but it represents a relative contraindication that requires careful risk-benefit assessment based on INR levels and bleeding risk.
Key Guideline Recommendations
The 2013 ACCF/AHA STEMI guidelines 1 do not list warfarin or oral anticoagulation as an absolute contraindication to fibrinolytic therapy. The absolute contraindications are limited to:
- Active internal bleeding
- History of intracranial hemorrhage
- Recent intracranial/intraspinal surgery or trauma (within 2-3 months)
- Known intracranial pathology (AVM, aneurysm, neoplasm)
- Known bleeding diathesis
- Severe uncontrolled hypertension
Similarly, the TNK drug label 2 lists "known bleeding diathesis" as a contraindication but does not specifically prohibit use in patients on warfarin.
Clinical Decision Framework
The critical factor is the INR level and overall bleeding risk:
- INR <1.7: Generally considered acceptable for thrombolysis in acute stroke settings based on evolving practice patterns
- INR ≥1.7: Traditionally considered higher risk, though recent evidence suggests benefit may still outweigh risk in selected patients
- Supratherapeutic INR: Represents significantly elevated bleeding risk
Evidence from Recent Practice
Recent data 3 examining patients on anticoagulants receiving thrombolysis or thrombectomy found no significant increase in intracranial hemorrhage rates in anticoagulated patients compared to non-anticoagulated patients, though this was a retrospective study requiring prospective validation.
Practical Algorithm
When encountering a patient on warfarin who needs TNK:
Check INR immediately if time permits
If INR <1.7 and no other contraindications exist: Proceed with TNK after weighing time-to-treatment urgency against bleeding risk
If INR ≥1.7: Consider:
- Severity of ischemia and territory at risk
- Time window for intervention
- Alternative reperfusion options (mechanical thrombectomy for stroke, PCI for STEMI)
- Potential for rapid reversal if absolutely necessary
Document risk-benefit discussion including consideration of:
- Large myocardium or brain territory at risk
- Hemodynamic instability
- Time delay to alternative interventions
- Patient/family preferences when feasible
Important Caveats
The 2017 ESC guidelines 4 emphasize that bleeding risk factors include:
- Lower weight
- Female sex
- Previous cerebrovascular disease
- Hypertension on admission
Patients on warfarin often have multiple bleeding risk factors (age, comorbidities, indication for anticoagulation), which compounds the decision complexity beyond the warfarin itself.
For STEMI patients: Primary PCI is strongly preferred over fibrinolysis when rapidly available, making the warfarin question less relevant in most contemporary practice settings.
For stroke patients: The benefit-to-risk ratio remains uncertain per evolving guidelines, but mechanical thrombectomy can be performed regardless of anticoagulation status and should be prioritized when large vessel occlusion is present.
Bottom Line
Being on warfarin is a relative—not absolute—contraindication to TNK. The decision hinges on INR level, bleeding risk stratification, urgency of reperfusion, and availability of alternative interventions. In life-threatening situations with large territory at risk and no rapid alternative, TNK can be administered even in anticoagulated patients after careful consideration, particularly if INR is not severely elevated.